Philippines grants EUA to Pfizer-BioNTech COVID-19 vaccine

The Philippine Food and Drug Administration (FDA) has granted emergency use authorization for Pfizer-BioNTech's COVID-19 vaccine.

The FDA determined that the benefits of the vaccine outweigh potential risks, with an efficacy rate of 95% in clinical trials.

Pfizer’s vaccine can be used for individuals aged 16 and older, requiring storage at -80 to -60 degrees Celsius before dilution.

While adverse events reported elsewhere are mostly mild and transient, the FDA will closely monitor any reactions post-immunization.

Sinovac Biotech has also applied for emergency use authorization, but the FDA needs additional clinical trial data from Sinovac.